Partnership between Novo Nordisk and Hims & Hers Health terminated due to unauthorized drug promotion in the GLP-1 weight loss market.
6 reports, 3 independent
Updated Aug 25
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 6
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Partnership between Novo Nordisk and Hims & Hers Health terminated due to unauthorized drug promotion in the GLP-1 weight loss market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Novo Nordisk and Hims & Hers are facing legal action over alleged consumer fraud and data misuse related to GLP-1.Sub-event
Novo Nordisk ended partnership with Hims & Hers Health over unauthorized drug promotion in the GLP-1 market.1 source
FTC probes Hims & Hers; Novo Nordisk faces potential GLP-1 lawsuit concerns.1 source
Keep exploring
Part of
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Also in this story
- Pfizer acquired Metsera after a bidding war with Novo Nordisk.
- Pfizer CEO Albert Bourla discussed company performance driven by cost control and AI, while UBS pressed on government policy impacts.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Eli Lilly and Novo Nordisk faced legal actions and partnership terminations regarding compliance and customer deception.
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Hims & Hers Health
American telehealth company
Nothing else this week.
Related events
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
- BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.
Coverage
Newest first; wire copies grouped- Simply Wall St.Is Regulatory Scrutiny and Novo Nordisk Partnership Loss Changing the Investment Case for Hims & Hers Health (HIMS)? Hims & Hers Health is facing a securities class action lawsuit following the past
- Investing.comHims & Hers stock drops after FTC probe report Investing.com -- Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed the Federa
- Insider MonkeyHims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is one of Monday'
- Unknown outlet
- Unknown outlet
- Unknown outlet